Compare PIII & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PIII | CTXR |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 13.4M |
| IPO Year | 2021 | 2010 |
| Metric | PIII | CTXR |
|---|---|---|
| Price | $1.63 | $0.51 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.75 | N/A |
| AVG Volume (30 Days) | 32.6K | ★ 253.3K |
| Earning Date | 11-09-2026 | 12-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,459,080,000.00 | N/A |
| Revenue This Year | $7.84 | N/A |
| Revenue Next Year | $7.13 | $104.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.52 | $0.37 |
| 52 Week High | $16.89 | $1.54 |
| Indicator | PIII | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 21.10 | 48.05 |
| Support Level | N/A | $0.47 |
| Resistance Level | $3.07 | $0.63 |
| Average True Range (ATR) | 0.39 | 0.06 |
| MACD | -0.08 | -0.00 |
| Stochastic Oscillator | 1.41 | 22.42 |
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all. It includes utilization management, care management, disease education, and maintenance of a quality improvement and quality management program for members assigned to the Company. The Company is also responsible for the credentialing of its providers, processing and payment of claims, and the establishment of a provider network for certain health plans.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.